Europäisches Patentamt
European Patent Office
Office européen des brevets

Bescheinigung Certificate Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02078953.3

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

Anmeldung Nr:
Application no.: 02078953.3
Demande no:

Anmeldetag:
Date of filing: 20.09.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Akzo Nobel N.V.
Velperweg 76
6824 BM Arnhem
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Live attentuated parasite vaccine

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s) revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K35/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Live attenuated parasite vaccine

The present invention relates to attenuated live parasites of the phylum Apicomplexa and the order of Kinetoplastida, to the use of such attenuated live parasites in a vaccine and in the manufacturing of such a vaccine, to vaccines comprising such attenuated live parasites, to methods for the production of such vaccines, to specific tet-repressor fusion proteins and to attenuated live parasites comprising such tet-repressor fusion proteins.

Within the regnum protozoa, the phylum of the Apicomplexa and the order of the Kinetoplastida, more specifically the family of Trypanosomatidae, are known to harbour several notoriously pathogenic parasites.
The family of Trypanosomatidae harbours i.a. parasites belonging to the genus Leishmania and Trypanosoma.

Leishmaniosis is a term for a variety of disease manifestations caused by Leishmania. The disease occurs most commonly in dogs and humans. The parasite is transmitted by sand flies to a mammalian host and is prevalent in all tropical and subtropical zones of the world. In the host parasites are taken up by macrophages where they stay and multiply, causing chronic inflammatory processes. Clinically, the disease in dogs is characterized by loss of weight, anaemia, pyrexia and lymphadenopathy. Cutaneous lesions are frequently observed. In humans multiple Leishmania species are infective, of which the most pathogenic is L. infantum, causing severe, visceral leishmaniosis (known as Kala azar), which effects spleen, liver and bone marrow, and is fatal if left untreated. Other pathogenic Leishmania species are i.e. L. major and L. mexicana.

Multiple species of trypanosomes are known, causing a variety of different diseases in both man and animal. Two trypanosome species in particular, are known to be pathogenic: Trypanosoma brucei and Trypanosoma cruzi.
T. brucei species are present in African countries and cause sleeping sickness in humans and Nagana in animals (cattle, horses, pigs). T. brucei is transmitted by the Tsetse fly, delivering the trypomastigote form into the host.
T. cruzi species are mainly present in South America, the parasite has a broad host range (including domestic and wild animals), but is famous for causing Chagas disease in man. The parasites are transmitted by cone-nosed bugs (like Rhodnius spp. and Triatoma spp.). The metacyclic trypomastigote stage infects the host and unlike T. brucei, will multiply inside the host cytoplasm of different cell types. After rupture of the host cell new trypomastigote forms are released which can again be ingested by cone nosed bugs.

The phylum Apicomplexa, harbours i.a. parasites of the family Eimeriidae. Many different Eimeria species are present in a large variety of mammals and birds. Seven prevalent species infecting the gastrointestinal tract of chickens are *Eimeria tenella, E. necatrix, E. brunetti, E. maxima, E. acervulina, E. praecox* and *E. mitis.* These Eimeria species are all involved in coccidiosis in poultry. This makes Eimeria the cause of the most important parasitic disease in poultry, causing great economically losses for farmers. Eimeria infects epithelial cells and submucosa of the intestines, causing severe hemorrhagic enteritis, which leads to high mortality in young birds. This disease has a world-wide distribution and is the most frequently recorded disease affecting poultry kept in modern poultry industry.

The family of sarcocystidae, comprising toxoplasma, sarcocystis and Neospora is also known to have pathogenic members.
Toxoplasma is a widespread parasitic infection, being present in almost all mammals, in particular in goat, sheep and pigs, but also in humans. Prevalence in human populations can be as high as 70% of the total population. Infection often occurs via eating of undercooked meat contaminated with the parasite, but can also occur by ingestion of oocysts, being spread in the faeces of cats, which are the final host. When animals or humans are infected during pregnancy, it can cause spontaneous abortion or congenital toxoplasmosis in the developing fetus. This can result in, neurological sequels or ocular disorders. Chronic and lethal infections (encephalitis) can occur in immune compromised patients.

Neospora, in particular N. caninum is a coccidian parasite very similar to Toxoplasma. However, in contrast to Toxoplasma, Neospora has the dog as final host. N. caninum induces abortions in its intermediate host, and can cause severe abortion storms in cattle. Another Neospora species, N. hughesi, is suspected to cause equine protozoal myeloencephalitis in horses.

Many Sarcocystis species are present in cattle, pigs, sheep, goats and horses. Economically, Sarcocystis neurona is recognized as the most common cause of clinical equine protozoal myeloencephalitis in horses. In the U.S. 50% of horses are seropositive for S. neurona.

Plasmodium belongs to the Haemosporida and is known i.a. as the cause of malaria, being transmitted by mosquitoes. In humans four Plasmodium species have been described, of which P. falciparum is the most pathogenic and deathly. 400 million people are estimated to be infected, causing two million deaths each year. Initial clinical symptoms are rhythmic fevers. After initial infection, Plasmodium parasitizes the red blood cells, often resulting in anemia. Parasitized red blood cells are sequestrated in capillaries of internal organs, thereby causing tissue anoxia. This is particularly serious in the brain, giving rise to multiple petechial hemorrhages, leading

to oedema and coma, which may be fatal. Although Plasmodium species have mainly been described in man, other Plasmodium species can infect al large variety of vertebrates.

Babesia and Theileria, both belonging to the Piroplasmids harbour parasite species affecting many mammalian species, and causing a variety of different diseases. Babesia species are transmitted by ticks and can infect a wide range of vertebrates causing a disease referred to as babesiosis. The disease is characterized by listlessness, anemia and parasitaemia leading to multi-organ dysfunction in infected animals. In advanced stages haemoglobinuria occurs. Important Babesia species in cattle include B. bovis, B. divergens, B. major and B. bigemina. In dogs B. canis, B. rossi, B. microti and B. gibsoni species are mainly causing babesiosis and are a common cause of death. Some Babesia species, like B. divergens and B. microti have been reported to infect humans as well.
Theileria is a tick-transmitted disease, infecting ruminants and is mainly a problem in cattle. Theileria infects and develops in leukocytes and erythrocytes. Pathology is mainly attributable to the intraleukocyte stage. Two major Theileria species should be discriminated in cattle, T. parva and T. annulata. T. parva causes East Coast Fever, a deathly cattle disease, being endemic in various African countries. East Coast Fever is characterized by high fever, lymphadenopathy, severe pulmonary oedema and wasting. T. annulata infects cattle and buffalo, first invading cells of the lymphatic system and later appearing in the peripheral blood as intra-erythrocyte forms. Infection with T. annulata is usually referred to as tropical theileriosis. The disease starts with high fever and swelling of lymph nodes, followed by listlessness, accelerated pulse and respiration rates and anorexia. In the final stage of disease anemia is observed and ultimately death occurs.
In the horse Babesia equi has been re-named as Theileria equi, also a major pathogen.

It is clear that different ways of attack against these parasites have been studies through the years.
One of the routes of combating parasitic infections is the use of pharmaceutical components, such as the extensive use of anticoccidials which nowadays is a very common therapy in the treatment of poultry coccidiosis. Another route is undoubtedly vaccination. It is clear that, especially where there is an increasing reluctance against the use of antibiotics, there is a need for new and effective vaccines, especially vaccines that provide broad protection.

Currently, two different approaches are used in vaccination against parasitic infections: vaccination with a live attenuated vaccine and vaccination with inactivated

(killed) vaccines. Both approaches have their advantages and disadvantages, as summarized below:

The main advantage of attenuated vaccines is that they closely mimic the natural infection: they activate all phases of the immune system, they can induce humoral IgG and local IgA, they raise immune responses to many protective antigens, they provide a more durable immunity and more cross-reactive. Moreover they are low-cost and they provide a quick immunity in the majority of cases.
Disadvantages of attenuated vaccines are the difficulties in finding the right level of attenuation and the possibility of reversion to virulence (these are major disadvantages), the spread to contacts of the vaccinee and the problems in immuno-compromised humans and animals.

Advantages of inactivated vaccines are that they provide sufficient humoral immunity if boosters are given, they show no mutation or reversion (a big advantage), they can be used with immuno-deficient patients, and in principle they are safe.
Disadvantages of inactivated vaccines: they often do not raise (cellular) immunity, boosters are needed, they provide no local immunity (important), they are more expensive and their use is dangerous if inactivation is below 100%.

Development of vaccines against parasites however is complex, if only because of the complexity of the parasites as such, when compared to other micro-organisms. Next to this, the various parasites even within the phylum Apicomplexa and within the family of Trypanosomatidae, although related, do not have sufficient similarity in their genetic make-up to allocate a common attenuation site or inactivation method, equally applicable to all these parasites. Moreover, for the manufacture of attenuated live vaccines it is necessary to locate suitable attenuation targets for each and every parasite. For the production of killed vaccines, one needs to know which antigens must be left unaltered by the inactivation method for each and every parasite. And apart from this, so far, inactivated parasite vaccines have not been shown to be effective. Finally, there is a variety of different infection routes, different hosts, different host cells within the host and often even host changes during the life cycle which is a characteristic of most parasites and which again differs from parasite to parasite. This also complicates the development of vaccines.

Therefore, the development of vaccines for combating parasitic infection so far has been difficult, time consuming and not very successful.

It is an objective of the present invention to provide vaccines for combating infections caused by parasites of the phylum Apicomplexa and the family of Trypanosomatidae, that combine most of the advantages of both killed and live attenuated vaccines almost completely without having the disadvantages of these vaccines. Moreover,

the method for the production of such vaccines is universally applicable to parasites of the phylum Apicomplexa and the family of Trypanosomatidae.

In the life cycle of all parasites of the phylum Apicomplexa and the family of Trypanosomatidae, there is at least one moment in which a certain stage infects a cell of a host and starts dividing. It was now surprisingly found that if ribosome synthesis can be stopped at or around the moment of infection, the parasite nevertheless does enter the host cell and divides several times using the present pool of ribosomes, thereby perfectly mimicking natural infection. Finally however, after several rounds of dividing, the progeny parasites will die due to lack of ribosomes.
This has the advantage that the induction of the immune response after infection is triggered in the most natural way, as if a virulent infection occurred, whereas contrary to the natural situation the parasite will after some time unavoidably become extinct. This goal was attained by placing a ribosomal protein gene under the control of an inducible promoter.

An inducible promoter is a promoter that can deliberately be switched on and off. Examples of such promoters will be given below.

In principle, each ribosomal protein gene can be used as a target, since in principle all ribosomal proteins are needed for the synthesis of a stable, fully functional ribosome.
All parasites of the phylum Apicomplexa and the family of Trypanosomatidae have cytoplasmatic ribosomes, and most of them have plastid ribosomes and/or mitochondrial ribosomes. All of these are necessary for the normal; development of the parasite. Therefore, live attenuated parasites according to the invention can be obtained by placing a ribosomal protein gene under the control of an inducible promoter, regardless the fact if this ribosomal protein gene encodes a ribosomal protein to be incorporated in plastid-, mitochondrial or cytoplasmatic ribosomes.

Ribosomal protein sequences are highly conserved between the various parasites. Therefore, DNA probes of the ribosomal sequences provided below can be used for the detection of the analogous ribosomal proteins in each of the parasites of the phylum Apicomplexa and the family of Trypanosomatidae. Additionally, the sequences of many ribosomal protein genes for many different parasites can be found in the NCBI-protein data base. (http://www.ncbi.nlm.nih.gov/)

The fact that the lack of one ribosomal protein can already disturb the formation of stable ribosomes has been demonstrated in various plants, animals and micro-organisms. Merely as an example: in Drosophila, mutations in some of the eighty ribosomal proteins have been shown to result in a typical phenotype, e.g. thin and

short bristles, prolonged development, and female semi-sterility in heterozygotes as well as homozygous lethality. This phenotype, termed Minute phenotype, has been observed with mutations in for example the ribosomal proteins S13, and L9, (Schmidt, A., Hollmann, M., Schäfer, U., Mol. Gen Genet. 251:381-387 (1996), Sæbøe-Larssen, S., Lambertsson, A., Genetics 143: 877-885 (1996)). Another example is the ribosomal protein gene YS3 of yeast, which encodes the yeast ribosomal protein S3. Its disruption yields non viable haploid spores of Saccharomyces cerevisiae (Finken-Eigen, M., Domdey, H., Köhrer, K., Biochemical and Biophysical research communications 223, 397-403 (1996)). These studies demonstrated that down-regulating a single ribosomal protein can already affect the formation and/or proper functioning of ribosomal complexes.

The promoters to be used in parasites according to the invention for the control of transcription of the ribosomal protein gene need to fulfil only one prerequisite. They must be switched on during the propagation of the parasites. This is of course necessary in order to provide the parasite according to the invention with the native amount of ribosomes necessary for normal propagation. The promoter must however be switched off in the recipient host that receives the parasite as a vaccine. A promoter is considered to be switched on if it initiates the transcription of the gene it controls. In the present invention this gene would be a ribosomal protein gene. A promoter is switched off if transcription of the gene that it controls is at least two times lower than in the native situation. Preferably, the level of transcription is at least 3, more preferably 4, still more preferably 5, 6 or even 7 times lower. It is stressed, that there is no need for a complete inhibition of transcription anyway. A low level of ribosomal protein transcription will finally result in an extended live span of the parasites, before they become extinct. Thus they will trigger the immune system for a somewhat longer period.
In principle, there are two different possibilities: either the promoter is switched on unless some condition is applied that switches the promoter off, or the promoter is switched off unless some condition is applied that switches the promoter on. Preferably, the promoter is in the switched off status unless some condition is applied that is not present in the recipient host that receives the parasite as a vaccine.
If necessary, two or more ribosomal protein genes can be placed under the control of inducible promoters. This would be a preferred option if the inducible promoter used in a promoter that can not be sufficiently switched off; i.e. if the inducible promoter is a leaky promoter, or in the exceptional case that lack of one specific ribosomal protein is not sufficient to destabilize the ribosome.

The invention will be explained by the following examples.
Toxoplasma gondii uses the cat as a final host, and uses herbi- and omnivores respectively carnivores as subsequent intermediate hosts. In the case of Toxoplasma, it is the tachyzoite stage of the parasite that ultimately infects humans.

Humans and warm-blooded animals are the target mammals for vaccination, and therefore the Toxoplasma tachyzoite is the parasitic stage for which the live attenuated parasite is needed. Therefore, the tachyzoite is the parasitic stage in which, according to the invention, a ribosomal protein gene is brought under the control of an inducible promoter. The thus made recombinant parasite, further also referred to as the attenuated live parasite, can be propagated in the classical way under conditions under which the promoter is switched on. Under these circumstances, the number of ribosomes will be identical or close to that in the native situation. If sufficient parasites are grown for vaccine purposes, the live attenuated parasites are collected and administered as a vaccine. In the host to be vaccinated, the conditions under which the promoter is switched on are not present and as a result the promoter will remain in the switched off situation. At the moment of vaccination, the parasite will behave as a wild-type parasite, because the pool of ribosomes is fully comparable to the native situation. Therefore, the process of infection, and of invasion of the host cell will perfectly mimic the process of natural infection. As soon as the parasite starts dividing in the host, it also divides the pool of ribosomes over its progeny. Since the promoter of (at least) one of the ribosomal protein genes is however in the switched off position when in the host cell, there will be either reduced or even no *de novo* synthesis of ribosomes. Therefore, the progeny will slowly become extinct. Nevertheless, in the meantime the process of infection, and therefore the triggering of the immune system has continued as in the case of a wild-type parasitic infection. Therefore, at the end of the day immunity will have build up as if an infection with a virulent wild-type parasite had taken place, whereas the live attenuated parasites used for the induction of immunity have become extinct after one or a few rounds of infection. The Examples below provide further details.

The life cycle of *Neospora caninum* is comparable with that of Toxoplasma except for the fact that Neospora uses dogs as the final host, and causes abortions in i.a. cattle, dogs, sheep and horses. The approach for Neospora vaccines thus closely relates to that of toxoplasma as described above. As for Toxoplasma, the tachyzoite is the parasitic stage in which, according to the invention, a ribosomal protein gene is brought under the control of an inducible promoter. The development of molecular genetics tools for Neospora has been described i.a. by Howe, D.K. and Sibley, L.D. METHODS: 13(2): 123-33 (1997))

For the production of a life attenuated *Eimeria* parasite, the merozoite is the parasitic stage in which, according to the invention, a ribosomal protein gene is brought under the control of an inducible promoter. In this case, the vaccine does not comprise the merozoite however, but the sporulated oocysts. This is due to the fact that the sporulated oocyst is the form in which the parasite is normally ingested by the

chicken. For the replication of the first recombinant merozoites made according to the invention, it suffices however to introduce these into the digestive tract of the chicken. Recombinant oocysts will then be shed by the chicken and can be isolated and directly used as the live attenuated parasite in coccidiosis vaccines, e.g. oral vaccines for administration to drinking water. Isolation of oocysts from chicken dung is a standard procedure well-known in the art. Genetic engineering of Eimeria has i.a. been described by Kelleher, M. and Tomley, F.M. (Mol Biochem Parasitol. 97(1-2): 21-31 (1998)).

A live attenuated malaria vaccine according to the invention can be made e.g. starting from erythrocyte stage plasmodium parasites. *Plasmodium* recombinant sporozoites. The sporozoite is the phase of the parasite that is injected into the (human) blood stream by the female mosquito. The sporozoite infects the liver within two minutes after injection, to produce schizonts and merozoites. The merozoites, in turn, infect erythrocytes and replicate there. It is at this moment in time that the pool of ribosomes must be divided over a large number of progeny parasites, and this is the moment at which the progeny parasites will become extinct. The whole immune defence system is already fully triggered at that moment in time. This example again illustrates the advantage of vaccines based upon recombinant parasites according to the present invention: they share all the advantages of live vaccines with the advantages of inactivated vaccines. Vaccination will preferably be done with either recombinant erythrocyte stage plasmodium parasites or (less practically) recombinant sporozoites. Recombinant DNA techniques for Plasmodium have been described i.a. by Crabb, B.S., et al., (Mol. Biochem. Parasitol. 90: 131-144 (1997)) and by Wu, Y. et al., (Proc. Natl. Acad. Sci., 93: 1130-1134 (1996), and Proc. Natl. Acad. Sci., 92: 973-977 (1995))

Live attenuated *Theileria* vaccines according to the invention can again be based upon recombinant merozoites. These merozoites can be grown and maintained in lymphocytes. It is in the lymphocyte that the merozoite starts dividing, synchronously with the division of the lymphocyte, while a few free progeny parasites will infect other lymphocytes, altogether leading to the induction of wild-type like immunity, however leading, as in the other examples, to progeny that finally becomes extinct due to slowly increasing lack of ribosomes. Theileria can be propagated and cultured in primary lymphoid cells. See e.g. Shkap V. et al., Vet Parasitol 65: 11-20 (1996) and Hulliger, L. J. Protozool. 12: 649-655 (1965).

Live attenuated *Babesia* vaccines can be made using the merozoites and/or trophozoites for recombination. These can be cultured in erythrocytes. The whole approach is comparable to that described for *Theileria* above. See i.a. Levy, M.G and Ristic, M. Science 207: 1218-1220 (1980).

For *Sarcocystus* species such as *S. suihominis* and *S. neurona*, both the sporozoite and the merozoite are targets for recombination according to the invention. And again, the principle is the same: the recombinant sporozoite provides recombinant merozoites and these merozoites slowly become extinct due to lack of ribosomes in the absence of *de novo* ribosome protein synthesis. The recombinant merozoites can be used directly in a vaccine. See e.g. Murphy, A.J. and Mansfield, L.S. J. Parasitol. 85: 979-981 (1999) and Ellison, S.P. et al., Vet. Parasitol. 95: 251-261 (2001).

As the order of Kinetoplastida is concerned, tetracycline regulated gene expression has been described for Trypanosoma brucei (Wirtz, E. and Clayton, C., Science 268: 1179- (1995), Biebinger, S. et al., Mol. & Biol. Parasitol. 85: 99-112 (1997)), Trypanosoma congolense (Inoue N., et al., Mol. & Biol. Parasitol. 120: 309-313 (2002)) and Leishmania donovani (Yan, S., et al., Mol. & Biol. Parasitol. 112: 61-69 (2001)), and can be adjusted to regulate ribosomal protein gene transcription as follows: briefly, the procyclic form of the parasite is the target for transfections. The tetracycline repressor is integrated into the non-transcribed spacers of the ribosomal RNA repeats, so that heterologous genes (in this case, a ribosomal gene) can be regulated in a tetracycline dependent manner. For the construction of live attenuated parasites according to the invention of the order of Kinetoplastida, first an extra copy of a ribosomal protein gene is inserted together with a promoter containing one or more tetracycline operator elements. Subsequently, the endogenous gene copy is deleted from the parasite genome. This can easily be done by homologous recombination preferably in the presence of a marker for recombination. This is comparable to methods for Apicomplexa as described below. (Direct targeting the endogenous ribosomal protein genes is not feasible for Leishmania and Trypanosoma, because most genes in Leishmania and Trypanosomes are organized into large (> 100-500 kb) polycistronic clusters of adjacent genes on the same DNA strand. Thus inhibition of one gene would lead to inhibition of the transcription of all the downstream localised genes (Myler, P.J. et al., Med. Microbiol. Immunol. 190: 9-12 (2001))).

The examples given above are indeed merely examples. They by no means limit the scope of the invention. Examples of all kinds of parasites of the phylum Apicomplexa and the family of Trypanosomatidae and their life cycles can be found in the Encyclopedic Reference of Parasitology, Heinz Mehlhorn, Springer Verlag (2001) (ISBN 3-540-66829-2). Man skilled in the art is thus perfectly able, with the examples given above and using the Encyclopedic Reference of Parasitology, to determine which stage would be the preferred stage as a starting point for making the live attenuated parasite according to the invention, for each parasite of the phylum Apicomplexa and the family of Trypanosomatidae.

Many of the parasites belonging to the families mentioned above have a variety of different hosts. Merely as an example: there are *Babesia* species such as *B. canis* infecting dogs, *B. caballi* infecting horses, mules and donkeys, *B. divergens* infecting cattle, wild ruminants and humans. Nevertheless, in all cases the parasitic life cycle is comparable. Therefore, where it is indicated above that a vaccine according to the invention against e.g. Babesia can be based upon recombinant merozoites, this holds true for all Babesia species. Details concerning the life cycles of the various species of one family can also be found in the Encyclopedic Reference of Parasitology, Heinz Mehlhorn, Springer Verlag (2001) (ISBN 3-540-66829-2), mentioned above.

Thus, one embodiment of the present invention relates to attenuated live parasites of the phylum Apicomplexa or the family of Trypanosomatidae that have as a characteristic that they comprise a ribosomal protein gene under the control of an inducible promoter.

The concept of inducible promoters has already been mentioned shortly above. An inducible promoter is a promoter that can be switched on and off under the influence of an external factor. Such a switching factor can be a physiological factor e.g. heat; the trigger of all of the many heat-shock promoters well-known in the art for decades already. Such a factor can also be of chemical nature. Many such factors are again well-known in the art. There are too many inducible promoters known in the art to mention them all. A few examples will be mentioned here. The IPTG-inducible Lac-promoter is possibly one of the most frequently used inducible promoters. Alternative inducible promoter systems are e.g. the tetracycline-controlled transactivation system (Baron, U. et al., Oxford University Press 25: 2723-2729 (1995)) and the ecdysone-inducible expression system (InVitrogen) (Yao, T.P. et al., Cell 71: 63-72 (1992)).

In principle there are two kinds of inducible promoters: those that are switched on in the presence of a condition, and those that are switched off in the presence of a condition. This condition may be the presence of a chemical substance.
A preferred form of this embodiment of the invention, the promoter to be used is switched on in the presence of a condition that is not naturally present in the host. The use of such promoters has the advantage that they automatically are in (or will switch to) the switched off position as soon as they are administered to the natural host of the parasite. This implies that a live attenuated parasite according to the invention is preferably grown under "artificial" conditions, i.e. conditions not present in the natural host, in order to replicate.

A preferred type of inducible promoters is the type of inducible promoters based upon an operator site and a repressor capable of reversibly binding said operator site. The binding and detachment of the repressor protein can then be regulated by the

"condition" applied as mentioned above, i.e. the presence or absence of heat, chemicals etcetera.

An very suitable example of an inducible promoter, or more precisely; a promoter/operator/repressor complex, that can very efficiently be used in attenuated live parasites according to the invention, is the tet-promoter/tet-operator complex, further also referred to as the tetR-system.

The tetR-system as such has been described and proven to work in many different protozoan parasites, such as T. brucei (Wirtz et al., Science 268:1179-1183 (1995), Biebinger et al., Mol. Biochem. Paras.85: 99-112 (1997)) and in E. hystolitica (Hamann et al., Mol. Biol. Paras. 84: 83-91 (1997)). The tetR-system was also successfully used in Toxoplasma to regulate expression of myosin A. (Meissner M, et al., Nucleic Acids Res. 29(22): E115 (2001)). In addition, tetracycline regulated expression was also demonstrated in *Giardia lamblia* and *Leishmania donovani*, showing its universal applicability in parasites. (Yan S, et al., Mol Biochem Parasitol.;112(1): 61-9 (2001), Sun, C.H. and Tai, Mol Biochem Parasitol. 105(1): 51-60 (2000)).

This complex operates as will be described shortly below and more extensively in the Examples.
In principle, two steps must be made in order to generate tetracycline regulated expression of ribosomal proteins: 1. integration and expression of a tetracycline repressor (tetR) gene and 2. integration of one or more tetracycline operator element(s) in the promoter of a ribosomal protein gene near the start of transcription. The tet-repressor gene is a gene that encodes a protein capable of binding to the tet-operator site thus blocking transcription of the adjacent gene. This gene is now placed under the control of a constitutive promoter (i.e. constitutive in the recombinant parasite) and brought into the parasite using recombinant DNA techniques. Thus, the recombinant parasite will synthesize the tet-repressor protein. The tet-operator is preferably introduced in the vicinity of the transcription start site of one or more ribosomal protein genes, preferably in the endogenous promoter. The tet-repressor protein will consequently bind to the tet-operator, thus blocking the transcription of the downstream ribosomal protein gene. In the presence however of tetracycline, the repressor will detach from the tet-operator site, thus enabling the transcription of the downstream gene. Therefore, in the presence of tetracycline, the recombinant parasite will be able to replicate as in the natural situation. If the recombinant parasite can be grown in vitro, as is the case for many parasites including most of the parasites of the examples given above, tetracycline can easily be added to the growth medium. If the growth of the parasites requires propagation in the natural host, which is e.g. the case for Eimeria parasites, tetracycline can easily be administered orally or by injection to the host (in this case the chicken). The

following should be noted: tetracycline is taken up by extracellular and intracellular parasites. Cell rupture of the host cell is not required for the drug to have effects on the regulation of the expression of ribosomal proteins.

Step 1, the integration and expression of the tetracycline repressor gene (tetR), can be obtained as described in the literature mentioned above. A suitable and well-known selection marker that indicates the stable transformation and possibly integration of the tetracycline repressor gene is e.g. the CAT-gene (Kim, K., et al., Science. 262(5135): 911-4 (1993). Other suitable markers for selection of stable transfection are also known in the art, such as DHFR-TS (Donald, R.G. and Roos, D.S., Proc Natl Acad Sci U S A. 90(24): 11703-7 (1993), Roos, D.S. et al., METHODS 13: 112-122 (1997)) and HXGPRT (Donald, R.G. et al., J. Biol. Chem 271: 14010-9 (1996), Donald, R.G. and Roos, D.S., Mol Biochem Parasitol. 91(2): 295-305 (1998)).

The Cre-*lox* system also provides a suitable selection system (see i.a. Hardy, S. et al., Journ. Virol. 71: 1842-1849 (1997)).

If the tetR-system is used as an inducible promoter system, the promoter upstream of the ribosomal protein gene can e.g. be the endogenous promoter, now made inducible by cloning the tet-operator in the vicinity of the start site of transcription (see below for details of the tet-operator sequence and preferred insertion sites). It goes without saying that any other promoter capable of providing a sufficiently high transcription level of the ribosomal protein gene is also suitable.

If another inducible promoter system is used, it would be easy to use that inducible promoter and delete the endogenous promoter. If however another regulatory element is used, of which the principle is comparable to the tet-operator, the promoter itself can equally well be the endogenous promoter. Again it goes without saying that any other promoter capable of providing a sufficiently high transcription level of the ribosomal protein gene cloned downstream, is also suitable.

The second step, replacement of a wild-type ribosomal protein gene with one containing one or more tetO sites (= tet-operator sites) in the vicinity of its promoter requires the insertion of the tet-operator site between the promoter of the ribosomal protein gene of choice and the gene itself. The tet-operator has been described by Yan S, et al. (Mol Biochem Parasitol.;112(1): 61-9 (2001)), by Wirtz, E and Clayton, C. (Science 268(5214): 1179-83 (1995)) and by Meissner M, et al. (Nucleic Acids Res. 29(22): E115 (2001)).

The sequence of a single tet operator (tetO) site is 5'-TCCCTATCAGTGATAGAGATC-3'. In principle, insertion of a single tet-operator site in front of the ribosomal protein gene of choice would suffice. The tetR-system is, as all biological systems, however not inducible from exactly 0% to 100% activity and

vice versa. Therefore, if a stronger level of regulation is needed, preferably two or more operator sites are inserted.
The tet-operator interferes with the binding of the RNA-polymerase that transcribes the downstream gene. Therefore, the tet-operator is preferably inserted somewhere in the region that extends from nucleotide –100 to +3 relative to the site at which the transcription starts (further also referred to as the STS). Moreover, in the Examples it is additionally described how to locate such STS.

The step of replacement of a wild-type ribosomal protein gene with a recombinant gene comprising one or more tet-operator sites can i.a. be performed with the hit-and-run strategy described by Donald, R.G. and Roos, D.S. (Mol Biochem Parasitol. 91(2): 295-305 (1998)).
The skilled artisan will be able to find alternative methods using other combinations of positive and negative selection markers. HSV Thymidine kinase can for example be used as a negative selection marker. (LeBowitz, J.H. et al., Mol Biochem Parasitol. 51(2): 321-5 (1992), Fox, B.A. et al, Mol Biochem Parasitol. 116(1): 85-8 (2001)).

The molecular tools used for the construction of toxoplasma parasites according to the invention work equally well in Neospora (Howe, D.K. and Sibley, L.D. METHODS 13(2): 123-33 (1997)).
In Eimeria, the same methods are equally applicable. Merely as an example: it was shown that beta-galactosidase could be transiently expressed in E. tenella by Kelleher, M. and Tomley, F.M. (Mol Biochem Parasitol. 97(1-2): 21-31 (1998)).
For Theileria, methods have e.g. been developed to transiently transfect infective, uninucleate, Theileria annulata sporozoites by Adamson, R. et al., Mol Biochem Parasitol. 114(1): 53-61 (2001)).
In Plasmodium, dihydrofolate reductase-thymidylate synthase (dhfr-ts) coding sequences mutated to confer resistance to pyrimethamine, or Puromycin-N-acetyltransferase, or the blasticidin S deaminase (BSD) gene of Aspergillus, or the neomycin phosphotransferase II (NEO) gene from transposon Tn5 have been described as selectable markers (Wu, Y., et al., Proc Natl Acad Sci U S A. 93(3): 1130-4 (1996), Wang, P., et al., Mol Biochem Parasitol. 123(1): 1 (2002), de Koning-Ward, T.F., et al., Mol Biochem Parasitol. 2001 Oct;117(2):155-60.
Similar selection markers work in Babesia as well.
Therefore, man skilled in the art will be able to apply the present invention over the full range of parasites belonging to the phylum Apicomplexa and the family of Trypanosomatidae.

A preferred form of this embodiment relates to attenuated live parasite according to the invention that belong to the Coccidia, the Piroplasmidae or the Haemosporida.

In a more preferred form of this embodiment, the attenuated live parasite belongs to the family Eimeridiidae, Cryptosporidiidae or Sarcocystidae.

In an even more preferred form of this embodiment, the attenuated live parasite belongs to the genus Eimeria, Cryptosporidium, Toxoplasma, Sarcocystis or Neospora.

In another more preferred form of this embodiment, the attenuated live parasite belongs to the family of the Babesiidae or the Theileriidae.

In an even more preferred form of this embodiment, the attenuated live parasite belongs to the genus Babesia or Theileria.

In another more preferred form of this embodiment, the attenuated live parasite belongs to the genus Plasmodium.

In still another more preferred form of this embodiment, the attenuated live parasite belongs to the genus Trypanosoma or the genus Leishmania.

In an even more preferred form, the attenuated parasite belongs to the species Leishmania mexicana, L. infantum or L. major or the species Trypanosoma brucei or T. cruzi

In another preferred form of this embodiment, a ribosomal protein gene of the live attenuated parasite according to the invention is under the control of an inducible promoter that is inducible by antibiotics.

More preferably, these antibiotics are tetracycline or anhydrotetracyclin, or derivatives thereof.

In another preferred form of this embodiment, the ribosomal protein gene of choice is the gene encoding L9, S3, plastid-S9 or S13, preferably the L9, S3, plastid-S9 or S13 of *Toxoplasma gondi*.

The nucleotide sequence of the gene encoding Large subunit ribosomal protein number 9 (L9), as well as upstream sequences comprising the promoter region is depicted in SEQ. ID. NO.: 1

REGION	1	2296	promoter	promoter region
REGION	2297	2461	e	exon 1
REGION	2416	2418	atg	atg start codon
GENE	2416	4831	cds	coding sequence
REGION	2462	3838	i	intron 1

REGION	3839	4260	e	exon 2
REGION	4261	4727	i	intron 2
REGION	4728	4834	e	exon 3
REGION	4829	4831	stop	TAA stopcodon

The nucleotide sequence of the gene encoding plastid Small subunit ribosomal protein number 9 (S9), as well as upstream sequences comprising the promoter region is depicted in SEQ. ID. NO.: 2

REGION	1	3076	promoter	promoter region
REGION	3077	3616	e	exon 1
REGION	3156	3158	atg	ATG start codon
GENE	3156	4325	cds	coding sequence
REGION	3617	3874	i	intron 1
REGION	3875	4034	e	exon 2
REGION	4035	4130	i	intron 2
REGION	4131	4338	e	exon 3
REGION	4323	4325	stop	TAG stop codon
REGION	4326	4338	3' utr	3' UTR

The nucleotide sequence of the gene encoding Small subunit ribosomal protein number 13 (S13), as well as upstream sequences comprising the promoter region is depicted in SEQ. ID. NO.: 3

REGION	1	1289	promoter	promoter region
REGION	1290	1594	e	exon 1
REGION	1448	1450	tg	ATG start codon
GENE	1448	3639	cds	coding sequence
REGION	1595	2527	i	intron 1
REGION	2528	2615	e	exon 2
REGION	2616	3489	i	intron 2
REGION	3490	3639	e	exon 3

The nucleotide sequence of the gene encoding Small subunit ribosomal protein number 3 (S3), as well as upstream sequences comprising the promoter region is depicted in SEQ. ID. NO.: 4

REGION	1	1177	promoter	promoter region
REGION	1178	1308	e	exon 1
REGION	1291	1293	atg	ATG start codon
GENE	1291	2651	cds	coding sequence
REGION	1309	1752	i	intron 1
REGION	1753	2137	e	exon 2
REGION	2138	2249	i	intron 2
REGION	2250	2389	e	exon 3

REGION	2390	2486	i	intron 3
GENE	2487	2748	e	exon 4
REGION	2649	2651	stop	TAA stop codon
REGION	2652	2748	3' utr	3' UTR

Attenuated live parasites according to the invention are very suitable for use in vaccines. This is, as extensively explained above, due to the fact that they combine the advantages of both live attenuated and inactivated vaccines, without suffering from the disadvantages.

Therefore, another embodiment of the present invention relates to attenuated live parasites according to the invention for use in a vaccine.

Still another embodiment of the invention relates to vaccines for combating parasitic infection that comprise a live attenuated parasite according to the invention and a pharmaceutically acceptable carrier.

A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer such as PBS, well-known in the art.

Vaccines according to the present invention may in a preferred presentation also contain an immunostimulatory substance, a so-called adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants frequently used in cow vaccines are muramyldipeptides, lipopolysaccharides, several glucans and glycans and Carbopol(R) (a homopolymer).
The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the protein adheres, without being covalently bound to it. Such vehicles are i.a. are lipid vesicles, iscoms, dendromers, niosomes, microparticles, especially chitosan-based microparticles, polysaccharide matrices and the like, bio-microcapsules, micro-alginates, liposomes and macrosols, all known in the art. Microparticles, more specifically those based upon chitosan, especially for use in oral vaccination are very suitable as vaccine vehicles.
A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)
In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween. Also, the vaccine may comprise one or more immune stimulantia such as cytokines, e.g. interferons.

Vaccines based upon live attenuated recombinant parasites described above can be administered in relatively low amounts, when compared to inactivated parasites, because they multiply themselves during the infection. Therefore, very suitable

amounts would range between 10^2 and 10^7 parasites per dose. Amounts below 10^2 parasites per dose may not always guarantee a sufficient level of protection in all vaccinated animals. Ranges from 10^7 up to 10^8 parasites per dose, although suitable, are not very practical, if only from an economic point of view.

Still another embodiment of the present invention relates to the use of an attenuated live parasite according to the invention for the manufacture of a vaccine for combating infection caused by a parasite of the phylum Apicomplexa or the family of Trypanosomatidae.

Again another embodiment of the present invention relates to methods for the production of a vaccine according to the invention that comprise the mixing of a live attenuated parasite according to the invention and a pharmaceutically acceptable carrier.

Vaccines according to the invention can be administered e.g. intradermally, subcutaneously, intramuscularly, intraperitoneally, intravenously, or at mucosal surfaces such as orally or intranasally.

The tet-repressor gene is a gene of prokaryotic origin. The codon usage for this gene is consequently sub-optimal in eukaryotic organisms such as the live attenuated parasites to which the present invention relates. Therefore, man skilled in the art would be motivated to adapt the coding sequence of the tet-repressor gene in such a way that it corresponds to the codon usage of the eukaryotic cell, thus arriving at a synthetic tet-repressor gene. This has been done by Meissner M, et al. (Nucleic Acids Res. 29(22): E115 (2001)).
Of course one would expect that this synthetic tet-repressor gene could not be further optimised, since it is already fully adapted to the eukaryotic cell. Moreover, one would expect this "synthetic" tet-repressor protein to be the best suitable repressor protein in the eukaryotic cell. This protein is in principle the same protein as the native protein, and thus by definition best fitted for interaction with the tet-operator site.

It was however surprisingly found now, that fusion proteins encoded by a recombinant gene comprising (part of) a heterologous gene fused to the N-terminal part of the native i.e. prokaryotic tet-repressor provide a significantly better regulation of the tet-operator than even the tet-repressor protein encoded by a fully eukaryote-adapted "synthetic" tet-repressor gene.
Thus, such fusion proteins would be the repressor proteins of choice to be used in the live attenuated parasites according to the present invention. This is even more an unexpected finding because 3D-structure studies of the tet-repressor protein would predict that N-terminal fusion would negatively interfere with DNA-binding. This was however surprisingly found not to be the case in practice.

A heterologous gene is any gene that encodes a protein other than the tet-repressor protein. A heterologous protein is any protein other than the tet-repressor protein. A recombinant gene is any artificially made gene that comprises (part of) a heterologous gene fused to that side of the tet-repressor gene that encodes the N-terminus of the tet-repressor protein.

The fusion protein must be able to reach the nucleus in order to interact with the tet-operator. Therefore there are a number of prerequisites to be fulfilled by the tet-repressor fusion protein: the final molecular weight of the monomeric tet-repressor fusion protein must be <60 kD, the heterologous part of the fusion protein must be on the N-terminal side of the tet-repressor protein, and the fusion protein must be free of GPI-anchors, secretion/excretion signals and trans-membrane regions. In principle, each and every protein or part thereof that meets with these prerequisites and (as a consequence) is capable of targeting the nucleus can be used for N-terminal fusion with the tet-repressor protein.
There is no need to use a full length heterologous protein for fusion. It suffices to use a part of such a heterologous protein. A part is considered to be a fragment of at least 10 amino acids, preferably a least 20 amino acids as the heterologous fusion protein.
Preferably, the part originates from the N-terminal side of the heterologous protein. Heterologous proteins of choice are e.g. Green, Red and Yellow Fluorescent protein and the CAT-protein.

Therefore, another embodiment of the present invention relates to DNA-fragments encoding a tet-repressor fusion protein that has as a characteristic feature that it comprises the tet-repressor protein and a heterologous protein or a part thereof, that is fused at the N-terminal side of the tet-repressor protein wherein the monomeric form of the fusion protein has a size of <60 kD and the fusion protein is free of GPI-anchors, secretion/excretion signals and trans-membrane regions.

Still another embodiment of the present invention relates to a tet-repressor fusion protein as such, that has as a characteristic feature that it comprises the tet-repressor protein and a heterologous protein or a part thereof, that is fused at the N-terminal side of the tet-repressor protein wherein the monomeric form of the fusion protein has a size of <60 kD and the fusion protein is free of GPI-anchors, secretion/excretion signals and trans-membrane regions.

The membranes to which the wording "trans-membrane regions" refers, are those membranes that are located between the cytoplasm of the cell and the outside world. These membranes specifically exclude the membranes between the nucleus and the cytoplasm. Preferably, the tet-repressor fusion protein according to the invention

does have some signals that specifically direct the fusion protein to the nucleus. This is clear, because the tet-repressor fusion protein (as is required for the native tet-repressor gene) has to enter the nucleus in order to be able to regulate the transcription of the gene it controls.

Due to its universal character, the combination of the tetR-system and the tet-repressor fusion protein can be used not only in live attenuated parasites according to the invention, but certainly also in other parasites and in other eukaryotic cells and organisms. It is universally applicable in eukaryotic cells, for the regulation of expression of any gene.

Attenuated live parasites according to the invention are thus even more suitable as a basis for vaccines, when such parasites comprise the tet-operator combined with (the genetic information encoding) the tet-repressor fusion protein described above. This allows an even better blocking and induction of the transcription of a ribosomal gene.

Therefore, in a more preferred form, attenuated live parasites according to the invention in which the induction of the gene is regulated by tetracycline, anhydrotetracyclin or derivatives thereof, comprise the tet-operator and the genetic information encoding a tet-repressor fusion protein as described above.

As will be shown in the examples, the unexpected characteristics of the tet-repressor fusion protein as described above are even more significant if two or more tet-operator sites are cloned in tandem. The wording "in tandem" should be interpreted broadly, in the sense that tet-operator sites may be cloned directly adjacent to each other or with a spacer sequence in between the two or more tet-operator sites. As mentioned before, the tet-operator sites are preferably cloned in the region between –100 and +3 relative to the STS.

Thus, in an even more preferred form, such attenuated live parasites according to the invention comprise not only the tetR-system and a tet-repressor fusion protein as described above, but also two or more tet-operator sites, instead of one.

EXAMPLES

Example 1.

Construction of TubYFP/TR-sagCAT (9332 bp).

Plasmid ptubYFP/TR-sagCAT was engineered stepwise as described below. First the construct ptubCAT/GFP was made by amplifying the *Toxoplasma gondii* tubuline A (tub) promoter from the ptubYFP/YFP-sagCAT construct (Llopsi, J. et al., PNAS 97(8): 4363-4368 (2000)) using the primers SAG3FW (#1) and TUB5RV (#2). The PCR product as well as the plasmid pdhfrCAT/GFP (Striepen, B. et al., Molecular and Biochemical Parasitology 92: 325-338 (1998)) were digested with HindIII and BglII, and ligated with each other. This resulted in ptubCAT/GFP where the dhfr promoter has been replaced by the tub promoter. The resulting plasmid is based on Bluescript pKS+ (Stratagene, La Jolla, CA) and contains the α-tubuline promoter separated from the fusion of chloramphenicol acetyl transferase (CAT) coding sequence with green fluorescent protein coding sequence by a BglII site.

To obtain the ptubYFP/TR construct the CAT coding sequence was exchanged for yellow fluorescent protein (YFP) and the GFP coding sequence was exchanged for tet-repressor coding sequence (tetR). The YFP gene was cut out of the ptubYFP/YFP-sagCAT construct by BglII and AvrII, and ligated between BglII and AvrII site of the ptubCAT/GFP construct replacing the CAT coding sequence. The tetR coding sequence was amplified by PCR from E. coli Tn10 (Hillen, W. and Berens, C., Annu.Rev.Microbiol. 48: 345-369 (1994)) using the primers TETAVR5-FW (#3) and TETPST3-RV (#4), digested by AvrII and PstI, and ligated in the construct by exchanging GFP coding sequence for the tetR coding sequence. The resulting plasmid was named ptubYFP/TR.

Finally a CAT selection cassette was inserted upstream of the tub promoter, resulting in the ptubYFP/TR-sagCAT plasmid. This was done by amplification of the CAT-cassette from the ptubYFP/YFP-sagCAT construct mentioned before using the primers T3(#5) and SAG/1634 RV(#6), digested with HindIII and ligated into the unique HindIII site of the ptubYFP/TR construct.

The construction of TubYFP/TR-sagCAT and its full sequence are presented in figure 1.

Example2

Determination of the start transcription site of the ribosomal protein gene S13 of Toxoplasma gondii

In order to determine the start of transcription of the ribosomal protein gene S13, RNA was isolated from *Toxoplasma gondii* RHΔHXGPRT tachyzoïtes grown in vero cells. Using the GeneRacer kit (Invitrogen) gene specific full-length cDNA was

obtained from the total RNA. With this kit a RNA oligo was ligated to the ends of full-length mRNA. After reverse transcription by oligo dT had taken place, amplification by PCR with a GeneRacer primer binding to the RNA oligo together with a gene specific primer resulted in a product. Then the start of transcription (STS) could be determined. This was done for the ribosomal protein gene S13 using the following primers: REV13A (#7) and REV13B (#8). Primer #7 was used together with the GeneRacer primer to get a product after which primer #8 was used for the nested PCR. The PCR product showed three bands; two weak bands and a strong band. The band showing the highest amount of product has been isolated and the STS was determined and indicated as 0.

Example 3.

S13/LZ constructs

In order to test inducible expression by the tet repressor several reporter constructs were made with the lacZ gene under control of the S13 promoter with or without the presence of a single tetO site. First the plasmid S13/lacZ was made (see figure 2 for the structure and sequence of the final construct) and subsequently this plasmid was used to insert or substitute sequences for a tetO site as described below.

The promoter region of S13 was amplified by PCR from the genomic DNA of the *Toxoplasma gondii* RH/ΔHXGPRT strain with the primers S13PROMFUS FW (#9) and S13PROMFUS RV (#10). The lacZ coding sequence was amplified by PCR from the genomic DNA of BL21 bacteria with the primers LACZ-AVRII FW (#11) and LACZ-PSTI RV (#12). Subsequently the S13 PCR product was digested by HindIII and XbaI while the lacZ PCR product was digested by AvrII and PstI. The plasmid ptubYFP/YFP-sagCAT was used to exchange the ptubYFP part together with the CAT selection cassette for the S13 promoter part. The remaining YFP gene was exchanged for the lacZ gene, resulting in S13/lacZ plasmid. The S13/lacZ plasmid was used to insert or substitute sequences for a single tet operator (tetO) site (5'-TCCCTATCAGTGATAGAGATC-3') by site-directed mutagenesis. This was done using the QuickChange site-directed mutagenesis kit (Stratagene). The tetO was inserted or substituted in the vicinity of the determined STS. The primers S13INSTETO+3 FW (#13) and S13INSTETO+3 RV (#14) were used to insert a tetO site at position +3 related to STS which is indicated as 0. The primers S13SUBTETO-23 FW (#15) and S13SUBTETO-23 RV (#16) were used to substitute sequences for a tetO site between –43 and –23 related to STS. These two constructs, S13instetO+3/lacZ and S13subtetO-23/lacZ together with the S13/lacZ construct have been tested in the *Toxoplasma gondii* strains RHΔHXGPRT, REP1/2 (Meissner, M. et al., Nucleic Acids Research 29 (22), e115 (2001)) and tubYFP/TR by a CPRG assay (Seeber, F. et al., Gene 169: 39-45 (1996)) in the absence or presence of tetR and (anhydro)tetracycline.

These constructs and the primers used are represented in figure 3.

Example 4

Selection of stable transfectant toxoplasma parasites carrying pTub-YFP-TR-sagCAT.

Electroporation of toxoplasma parasites was done as described by Roos, D.S. et al. (Methods in Microbial Pathogenesis" in Methods in Cell Biology (1994), D.G. Russell, editor).

Selection of the stable transfectants was done according to Kim, K., et al. (Science. 262(5135): 911-4 (1993)).

Electroporation of S13/LZ, S13i+3/lacZ and S13s-23/lacZ constructs was again done according to Roos, D.S. et al. (Methods in Microbial Pathogenesis" in Methods in Cell Biology (1994), D.G. Russell, editor).

Results:

Determination of LacZ expression driven by an S13 promoter containing a single tet-operator, electroporated into the tub-YFP-TR strain.

The following constructs have been tested:

a) S13/LZ. This is the tub-YFP-TR transfectant toxoplasma strain, transiently transfected with the LacZ gene under the control of the S13 ribosomal protein gene promoter. There is no tet-operator-site present in this construct.

b) S13i+3/lacZ. This is the tub-YFP-TR transfectant toxoplasma strain, transiently transfected with the LacZ gene under the control of the S13 ribosomal protein gene promoter which additionally carries a tet-operator-site inserted at site +3 relative to the STS (see figure 3).

c) S13s-23/lacZ. This is the tub-YFP-TR transfectant toxoplasma strain, transiently transfected with the LacZ gene under the control of the S13 ribosomal protein gene promoter which additionally carries a tet-operator-site has been substituted at site -23 relative to the STS (see figure 3).

As can be seen in figure 4, tub-YFP-TR produces the same level of LacZ in both the presence and absence of anhydro-tetracycline and tetracycline, as expected.

Transfection with construct S13i+3/lacZ results in the production of an amount of LacZ in the absence of anhydro-tetracycline and tetracycline, that is half the amount of LacZ produced in the presence of anhydro-tetracycline and tetracycline. This clearly shows the inducibility of LacZ-transcription in this strain.

Transfection with construct S13s-23/lacZ results in the production of an amount of LacZ in the absence of anhydro-tetracycline and tetracycline, that is about 1/3 of the amount of LacZ produced in the presence of anhydro-tetracycline and tetracycline. This again clearly shows the inducibility of LacZ-transcription in this strain.

These results moreover prove that the site at which the tet-operator site is located relative to the STS, is not very critical. It additionally proves that the tet-operator site may be introduced by both insertion and substitution.

CPRG-assay of transient transfectants electroporated with a construct comprising a LacZ gene driven by an S13 promoter comprising a single tet-operator or a double tet-operator.

In this assay the following constructs were compared:
a) S13/LZ as described above
b) S13s-23/lacZ(I) as described above (= S13s-23/lacZ)
c) S13s-23/lacZ(II) which equals S13s-23/lacZ except for the fact that an additional tet-operator site has been cloned immediately downstream of the first tet-operator.

As follows from figure 5, both the synthetic tet-repressor gene (Meissner) mentioned above and a fusion tet-repressor gene (tub-YFP-TR) according to the invention are capable of blocking the transcription of LacZ in the absence of tetracycline. More strikingly, it clearly follows that the blocking of expression is between 3 and 4 times better when two adjacent tet-operator sites are used compared to the use of a single tet-operator.

CPRG-assay of transient transfectants comparing LacZ expression in a strain comprising the synthetic tet-repressor gene (Meissner) as described above, and a strain comprising a fusion tet-repressor gene according to the invention.

As follows surprisingly from figure 5, a fusion tet-repressor protein according to the invention gives a significantly better blocking of the transcription of LacZ when compared to the blocking found with synthetic tet-repressor protein (Meissner) as described above.

Also, surprisingly, a much better induction of LacZ transcription is found with a fusion tet-repressor gene according to the invention when compared to the induction found with synthetic tet-repressor gene (Meissner) mentioned above.

Legend to the figures.

Figure 1: schematic drawing of TubYFP/TR-sagCAT and full sequence of the construct.

Figure 2: schematic drawing of S13/LacZ and full sequence of the construct.

Figure 3: Sequence of part of the ribosomal protein S13-promoter, also indicating the site of the +3 insertion and the –23 substitution, relative to the STS. Also indicated are the first three amino acids of the coding region.

Figure 4: Determination of the level of LacZ expression in tubYFP/TR electroporated with the constructs S13/LZ, S13i+3/lacZ and S13s-23/lacZ without antibiotics, in the presence of 1 µg/ml anhydro-tetracycline (Atc) or in the presence of 1 µg/ml tetracycline (Tc). The OD is an indication for the level of LacZ expression. The graph indicates that $1.25x10^6$ tachyzoïtes were used (50 % of originally made amount).

Figure 5: determination of the LacZ expression level in different strains (RH, REP, tubYFP/TR) electroporated with the constructs S13/LZ, S13s-23/lacZ(I) and S13s-23/lacZ(II)
RH represents the strain without tet-repressor gene. REP represents the strain carrying the synthetic tet-repressor gene (Meissner). TYT represents the strain carrying the fusion tet-repressor gene (tub-RFP-TR). Equal amounts of cells have been used in these comparative experiments. Experiments have been done in the absence or presence of tetracycline as indicated in the figure.

Claims

1) Attenuated live parasite of the phylum Apicomplexa or the family of Trypanosomatidae, characterized in that said parasite comprises a ribosomal protein gene under the control of an inducible promoter.
2) Attenuated live parasite according to claim 1, characterized in that said parasite belongs to the Coccidia, the Piroplasmidae or the Haemosporida
3) Attenuated live parasite according to claim 2, characterized in that said parasite belongs to the family of the Eimeridiidae, Cryptosporidiidae or Sarcocystidae.
4) Attenuated live parasite according to claim 3, characterized in that said parasite belongs to the genus Eimeria, Cryptosporidium, Toxoplasma, Sarcocystis or Neospora.
5) Attenuated live parasite according to claim 2, characterized in that said parasite belongs to the family of the Babesiidae or the Theileriidae.
6) Attenuated live parasite according to claim 5, characterized in that said parasite belongs to the genus Babesia or Theileria.
7) Attenuated live parasite according to claim 2, characterized in that said parasite belongs to the genus Plasmodium.
8) Attenuated live parasite according to claim 1, characterised in that said parasite belongs to the genus Trypanosoma or the genus Leishmania
9) Attenuated live parasite according to claims 1-8, characterised in that said inducible promoter is based upon an operator site and a repressor protein capable of reversibly binding said operator site.
10) Attenuated live parasite according to claims 1-9, characterized in that said inducible promoter is inducible by antibiotics.
11) Attenuated live parasite according to claim 10, characterized in that said inducible promoter is inducible by tetracycline or anhydrotetracyclin, or a derivative thereof.
12) Attenuated live parasite according to claim 11, characterized in that a tetR-system is used as the inducible promoter.
13) Attenuated live parasite according to claims 1-12, characterized in that said ribosomal protein gene is the gene encoding L9, S3, plastid S9 or S13, preferably L9, S3, plastid S9 or S13 of *Toxoplasma gondi*.
14) Attenuated live parasite according to claims 1-13 for use in a vaccine.
15) Vaccine for combating parasitic infection characterized in that said vaccine comprises a live attenuated parasite according to claims 1-13 and a pharmaceutically acceptable carrier.
16) Use of an attenuated live parasite according to claims 1-13 for the manufacture of a vaccine for combating infection caused by a parasite of the phylum Apicomplexa or the family of Trypanosomatidae.

17) Method for the production of a vaccine according to claim 15, said method comprising the mixing of a live attenuated parasite according to claims 1-13 and a pharmaceutically acceptable carrier.

18) DNA-fragment encoding a tet-repressor fusion protein comprising the tet-repressor protein and a heterologous protein or a part thereof, said heterologous protein or a part thereof being fused to the N-terminal side of the tet-repressor protein, the monomeric form of said fusion protein having a molecular weight of less than 60 kD and being free of GPI-anchors, secretion/excretion signals and trans-membrane regions.

19) Attenuated live parasite according to claims 1-13, characterised in that said parasite comprises the tet-operator site and a DNA fragment encoding a tet-repressor fusion protein according to claim 18.

20) Attenuated live parasite according to claim 19, characterised in that said parasite comprises two or more tet-operator sites.

Abstract.

The present invention relates inter alia to attenuated live parasites of the phylum Apicomplexa and the family of Trypanosomatidae and to the use of such attenuated live parasites in a vaccine and in the manufacturing of such a vaccine. Furthermore, the present invention relates to vaccines comprising such attenuated live parasites and to methods for the production of such vaccines. Finally, the invention relates to specific tet-repressor fusion proteins and to attenuated live parasites according to the invention comprising such tet-repressor fusion proteins.

Figure 1.

```
   1  gtggcacttt tcggggaaat gtgcgcggaa ccccatatttg tttatttttc taaatacatt
  61  caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa tattgaaaaa
 121  ggaagagtat gagtattcaa catttccgtg tcgcccttat tcccttttt gcggcatttt
 181  gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct gaagatcagt
 241  tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc cttgagagtt
 301  ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta tgtggcgcgg
 361  tattatcccg tattgacgcc gggcaagagc aactcggtcg ccgcatacac tattctcaga
 421  atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc atgacagtaa
 481  gagaattatg cagtgctgcc ataaccatga gtgataacac tgcggccaac ttacttctga
 541  caacgatcgg aggaccgaag gagctaaccg ctttttgca caacatgggg gatcatgtaa
 601  ctcgccttga tcgttgggaa ccggagctga atgaagccat accaaacgac gagcgtgaca
 661  ccacgatgcc tgtagcaatg gcaacaacgt tgcgcaaact attaactggc gaactactta
 721  ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagtt gcaggaccac
 781  ttctgcgctc ggcccttccg gctggctggt ttattgctga taaatctgga gccggtgagc
 841  gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc cgtatcgtag
 901  ttatctacac gacgggagt caggcaacta tggatgaacg aaatagacag atcgctgaga
 961  taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca tatatacttt
1021  agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc ctttttgata
1081  atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca gaccccgtag
1141  aaaagatcaa aggatcttct tgagatcctt ttttctgcg cgtaatctgc tgcttgcaaa
1201  caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta ccaactcttt
1261  ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt ctagtgtagc
```

2/1

```
1321  cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc gctctgctaa

1381  tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg ttggactcaa

1441  gacgatagtt accggataag gcgcagcggt cgggctgaac ggggggttcg tgcacacagc

1501  ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag ctatgagaaa

1561  gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa

1621  caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat agtcctgtcg

1681  ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg gggcggagcc

1741  tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc tggccttttg

1801  ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgcctttg

1861  agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg

1921  aagcggaaga gcgcccaata cgcaaaccgc ctctccccgc gcgttggccg attcattaat

1981  gcagctggca cgacaggttt cccgactgga aagcgggcag tgagcgcaac gcaattaatg

2041  tgagttagct cactcattag gcaccccagg ctttacactt tatgcttccg gctcgtatgt

2101  tgtgtggaat tgtgagcgga taacaatttc acacaggaaa cagctatgac catgattacg
                                                         KpnI
                                                        ------
2161  ccaagcgcgc aattaaccct cactaaaggg aacaaaagct gggtaccggg ccccccctcg
                 >>........T3 ........>>
                           HindIII                PstI
                           -------               -------
2221  aggtcgacgg tatcgataag cttgatatcg aattcctgca gcccccgaga cgcgtgttct
                                                                 >>.pSAG1.>

2281  aaccacaaac cttgagacgc gtgttccaac cacgcaccct gacacgcgtg ttccaaccac
      >..........................pSAG1..............................>

2341  gcaccctgag acgcgtgttc tawccacgca ccctgagacg cgtgttctaa ccacgcaccc
      >..........................pSAG1..............................>

2401  tgagacgcgt gttctgccgc acaatgtgca cctgtaggaa gctgtagtca ctgctgattc
      >..........................pSAG1..............................>

2461  tcactgttct cggcaagggc cgacgaccgg agtacagttt ttgtgggcag agccgttgtg
      >..........................pSAG1..............................>
```

```
2521  cagctttccg ttcttctcgg ttgtgtcaca tgtgtcattg tcgtgtaaac acacggttgt
      >.............................pSAG1.............................>>

2581  atgtcggttt cgctgcacca cttcattatt tcttctggtt ttttgacgag tatgcatgag
      >>>
      >>.........................SAG1 CDS.........................>>
                                                                  >>>
                                                                     >>>

2641  aaaaaaatca ctggatatac caccgttgat atatcccaat ggcatcgtaa agaacatttt
      >.............................CAT CDS.............................>

2701  gaggcatttc agtcagttgc tcaatgtacc tataaccaga ccgttcagct ggatattacg
      >.............................CAT CDS.............................>

2761  gccttttttaa agaccgtaaa gaaaaataag cacaagtttt atccggcctt tattcacatt
      >.............................CAT CDS.............................>

2821  cttgcccgcc tgatgaatgc tcatccggaa ttccgtatgg caatgaaaga cggtgagctg
      >.............................CAT CDS.............................>

2881  gtgatatggg atagtgttca ccccttgttac accgttttcc atgagcaaac tgaaacgttt
      >.............................CAT CDS.............................>

2941  tcatcgctct ggagtgaata ccacgacgat ttccggcagt ttctacacat atattcgcaa
      >.............................CAT CDS.............................>

3001  gatgtggcgt gttacggtga aaacctggcc tatttcccta aagggtttat tgagaatatg
      >.............................CAT CDS.............................>

3061  tttttcgtct cagccaatcc ctgggtgagt ttcaccagtt ttgatttaaa cgtggccaat
      >.............................CAT CDS.............................>

3121  atggacaact tcttcgcccc cgttttcacc atgggcaaat attatacgca aggcgacaag
      >.............................CAT CDS.............................>

3181  gtgctgatgc cgctggcgat tcaggttcat catgccgttt gtgatggctt ccatgtcggc
      >.............................CAT CDS.............................>

3241  agaatgctta atgaattaca acagtactgc gatgagtggc agggcggggc ktaaktratc
      >.........................CAT CDS.........................>>
                                                              >>...>

3301  accgttgtgc tcacttctca aatcgacaaa ggaaacacac ttcgtgcagc atgtgcccca
      >.............................SAG1-I.............................>

3361  ttataaagaa actgagttgt tccgctgtgg cttgcaggtg tcacatccac aaaaaccggc
      >.............................SAG1-I.............................>

3421  cgactctaaa taggagtgtt tcgcagcaag cagcgaaagt ttatgactgg gtccgaatct
      >.............................SAG1-I.............................>
```

```
3481  ctgaacggat gtgtggcgga cctggctgat gttgatcgcc gtcgacacac gcgccacatg
      >.........................SAG1-I.........................>

3541  ggtcaataca caagacagct atcagttgtt ttagtcgaac cggttaacac aattcttgcc
      >.........................SAG1-I.........................>
            HindIII
            -------
3601  cccccgaaag cttcgaatct ctgaacggat gtgtggcgga cctggctgat gttgatcgcc
      >....>>
                  >>.....................SAG1-II.....................>

3661  gtcgacacac gcgccacatg ggtcaataca caagacagct atcagttgtt ttagtcgaac
      >.........................SAG1-II.........................>

3721  cggttaacac aattcttgcc cccccgaggg ggatccacta gttctagagc ggcctcgagg
      >.........SAG1-II..........>>
                                  >>.............vector.............>

3781  tcgacggtat cgataagcta gagcttcagc atcatctctg gaagcatccc ctgaactgcc
      >.....vector......>>
                        >>..................pTUB1.................>

3841  tgagtctacc aagagcactg gcgaaggctg tgagtagtcg gacaggcacg gtgactcatg
      >.........................pTUB1.........................>

3901  ttgttggaca gtagcgagct ctgggttaac cgcatattca ctaactggct ccgtcctgtt
      >.........................pTUB1.........................>

3961  gtcattagat actgaatcag gtaacgatac atgagcagca tcctcgtgtt ccaggcgcat
      >.........................pTUB1.........................>

4021  gtcctgctcc ggcttgcaac caaggacccg tggttcatct ttgggtctct ccgtactggg
      >.........................pTUB1.........................>

4081  tggtagaggt gaaactgtcg acgtggatgc agctgccctg cttagagtac ggacgaagtg
      >.........................pTUB1.........................>

4141  aatagctgcg tctgcatgaa caaggggctc tgaggcccgc tgtgatacga aaggtttgct
      >.........................pTUB1.........................>

4201  ggctactgaa cataggtctc gcagtgcggg ggcatactcc agtcggcctt cacgaaactt
      >.........................pTUB1.........................>

4261  cgtgaccagg cgatcaacaa gcggcgtcac gcgagttaaa tccgtccaga gaaagccacc
      >.........................pTUB1.........................>

4321  atagtgcacc atatactgcc ggcacatctt gctgaaagtc gtggcgtgtc gatcagctaa
      >.........................pTUB1.........................>

4381  gtcctgtgtg tacttggaag tgagcagctc ttccagttcg gtccagtcat attgccatgc
      >.........................pTUB1.........................>
```

```
4441  cctagccacc gtttcaccag cgtccgatgc aggctcacct agccgatacc tgtgaccgtt
      >.............................pTUB1.............................>

4501  catatatgag ttgctattac atctgtcggc cgtaacgaca caaggagatg cggctggagg
      >.............................pTUB1.............................>

4561  caacgggttt gtgagcacca ttttgactct gtcacggagt aaaaaacatt tattcgaact
      >.............................pTUB1.............................>

4621  ttgtacgagc gcagtcagta gaagtcaacc acgcgtatca actacgctgc aattacagag
      >.............................pTUB1.............................>

4681  gacagggaca gggaaaaaaa gccgaagagg ttgccggtgt taggagatga cgagacgttt
      >.............................pTUB1.............................>

4741  aaacggccgc tggctattgt tcgggcatcg ttgagccaca agcgatcaag gtgaaaacaa
      >.............................pTUB1.............................>

4801  agttaaatag ttatgctgga gcgattgccc tgctgaatct tcagatcgga cgaacagtca
      >.............................pTUB1.............................>

4861  ttctggccca ctgtacttga tgtgttcgat gtaaatcaca ctcagtcgcg tgctcggtag
      >.............................pTUB1.............................>

4921  caatcaagtt gctcttttct ctcctttcta gacacggtaa gaacgcttat gaacacgcat
      >.............................pTUB1.............................>

4981  acacgcatag tttttgctag aatgcagcga ccagatgtcg caaggtcgtc tcccccatcg
      >.............................pTUB1.............................>

5041  actggagaat caagaaaaac ctgcgttgat cccaaacgta ctctgtggtt ggtgcaacca
      >.............................pTUB1.............................>

5101  gaagtttcat actgatcaaa agccagtgaa cagctggggg acattgcagg tctggtgctt
      >.............................pTUB1.............................>

5161  caagaagcgc tgaagaagaa agtggcgaaa cctcggcag ttgccttgga agaggcgccg
      >.............................pTUB1.............................>

5221  tgcatgtaac ttctgaagtg cgtagtacct ggctcctaat gctgttttgt gtttcgctgt
      >.............................pTUB1.............................>

5281  ctgggcagca gtagaatgct gtgccagaat tagccactat tttagacatt tatttacaca
      >.............................pTUB1.............................>

5341  ttttttttct gatgaacttg gcttattcat tttttcaagt cttgccactg ggtggtggca
      >.............................pTUB1.............................>

5401  tgagactcgc ttagatgtat gtgggtgttg caatcacgct ggatgctcgg cttatttctg
      >.............................pTUB1.............................>
```

```
5461  agtttttgt ggttttgaca atgggaacga tttcagagct actatttcac gtggtacggt
      >.............................pTUB1.............................>

5521  tatgagccac taaaaaaacg aagaaaaacg ctgtttgcag aaacaatagc aaactgtttt
      >.............................pTUB1.............................>

5581  tcgtcatagt aactcagcgc ccccttgccc ccccccagca gtgagatgca agacaatcct
      >.............................pTUB1.............................>

5641  ctctaccaca gcttttgttg cgtctgtttc aaattttcag cgctcgcgaa aggcatcacg
      >.............................pTUB1.............................>

5701  aacaacatta tgagagggag caggtttgtg gggctggcgg gtgcaggaat gtgttcctgc
      >.............................pTUB1.............................>

5761  gaaaaaggcc tctgctgaga aggtcgtggc gtttgaaaaa tatccgaggt agcaaagact
      >.............................pTUB1.............................>

5821  tgtttcagtg ctccccttttt gaagacctgc ggcggcagtg cactgaagag taactccaaa
      >.............................pTUB1.............................>

5881  tcaccgcggt gagacttggt ttttttcgtt atccttcaga agagtgtgtt ttcgtttaat
      >.............................pTUB1.............................>

5941  tcgtcacaga ccacgaaaaa cgaaccatcg aagacgatca ctgcgtccgc gtgcatctgg
      >.............................pTUB1.............................>

6001  atggatgacc cacatctgtt gcagccgtcg cagacatgca tgtcccgcgt tcgtgaaatt
      >.............................pTUB1.............................>

6061  ctctgcatca gcggagtgat caggaatcat cgtctcagcg ggatgacgtt gcggagcagg
      >.............................pTUB1.............................>

6121  ccggctcgcg ggggcagtca gatgccgaag gcgtaactca ggacgcttgc gctcatcgca
      >.............................pTUB1.............................>

6181  gaacaggggt ggtgcctgca ttgggtgcgg ttggtgatcc tggttggacc ggtggagatg
      >.............................pTUB1.............................>

6241  cgcgcgcacg aaggggatgt gtcagaaaca ttttgtttgt tctctgtgaa cttttagatg
      >.............................pTUB1.............................>

6301  tgttaaaggc ggcgaatatt agcagagagt cctccttgtt ggattctctc ttgaatttcg
      >.............................pTUB1.............................>

6361  ccctttcctt ctctttgcga gtctcgtaga gaacaagcac tcgttcgccg tccctgacga
      >.............................pTUB1.............................>

6421  cgcaacccgc gcagaagaca tccaccaaac ggtgttacac aatcaccttg tgtgaagttc
      >.............................pTUB1.............................>
```

```
                                                   BglII
                                                   ------
6481  ttgcggaaaa ctactcgttg gcattttttc ttgaattccc agatctaaaa tggtgagcaa
      >................pTUB1.................>>
                                                              >>.YFP CDS.>
                                                              >>>>

6541  gggcgaggag ctgttcaccg gggtggtgcc catcctggtc gagctggacg gcgacgtaaa
      >..........................YFP CDS...........................>

6601  cggccacaag ttcagcgtgt ccggcgaggg cgagggcgat gccacctacg gcaagctgac
      >..........................YFP CDS...........................>

6661  cctgaagttc atctgcacca ccggcaagct gcccgtgccc tggcccaccc tcgtgaccac
      >..........................YFP CDS...........................>
                 PstI
                 ------
6721  cttcggctac ggcctgcagt gcttcgcccg ctaccccgac cacatgaagc agcacgactt
      >..........................YFP CDS...........................>

6781  cttcaagtcc gccatgcccg aaggctacgt ccaggagcgc accatcttct tcaaggacga
      >..........................YFP CDS...........................>

6841  cggcaactac aagacccgcg ccgaggtgaa gttcgagggc gacaccctgg ygaaccgcat
      >..........................YFP CDS...........................>

6901  cgagctgaag ggcatcgact tcaaggagga cggcaacatc ctggggcaca agctggagta
      >..........................YFP CDS...........................>

6961  caactacaac agccacaacg tctatatcat ggccgacaag cagaagaacg gcatcaaggt
      >..........................YFP CDS...........................>

7021  gaacttcaag atccgccaca acatcgagga cggcagcgtg cagctcgccg accactacca
      >..........................YFP CDS...........................>

7081  gcagaacacc cccatcggcg acggccccgt gctgctgccc gacaaccact acctgagcta
      >..........................YFP CDS...........................>

7141  ccagtccgcc ctgagcaaag accccaacga gaagcgcgat cacatggtcc tgctggagtt
      >..........................YFP CDS...........................>
                                                           AvrII
                                                           -------
7201  cgtgaccgcc gccgggatca ctctcggcat ggacgagctg tacaagccta ggatgtctag
      >...................YFP CDS...................>>
                                                                  >>.....>
                                                                  >>>

7261  attagataaa agtaaagtga ttaacagcgc attagagctg cttaatgagg tcggaatcga
      >...........................TR CDS...........................>

7321  aggtttaaca acccgtaaac tcgcccagaa gctaggtgta gagcagccta cattgtattg
      >...........................TR CDS...........................>

7381  gcatgtaaaa aataagcggg ctttgctcga cgccttagcc attgagatgt tagataggca
      >...........................TR CDS...........................>
```

8/1

```
7441  ccatactcac ttttgccctt tagaagggga aagctggcaa gatttttac gtaataacgc
      >.........................TR CDS.........................>

7501  taaaagtttt agatgtgctt tactaagtca tcgcgatgga gcaaaagtac atttaggtac
      >.........................TR CDS.........................>

7561  acggcctaca gaaaaacagt atgaaactct cgaaaatcaa ttagcctttt tatgccaaca
      >.........................TR CDS.........................>

7621  aggtttttca ctagagaatg cattatatgc actcagcgct gtggggcatt ttactttagg
      >.........................TR CDS.........................>

7681  ttgcgtattg gaagatcaag agcatcaagt cgctaaagaa gaaagggaaa cacctactac
      >.........................TR CDS.........................>

7741  tgatagtatg ccgccattat tacgacaagc tatcgaatta tttgatcacc aaggtgcaga
      >.........................TR CDS.........................>

7801  gccagccttc ttattcggcc ttgaattgat catatgcgga ttagaaaaac aacttaaatg
      >.........................TR CDS.........................>
                        PstI
                        -------
7861  tgaaagtggg tcttaactgc agcccacaga agctgcccgt ctctcgtttt cctctctttt
      >....TR CDS....>>
                              >>.............DHFR.............>

7921  cggagggatc agggagagtg cctcgggtcg gagagagctg acgagggggt gccagagacc
      >.........................DHFR.........................>

7981  cctgtgtcct ttatcgaaga aaagggatga ctcttcatgt ggcatttcac acagtctcac
      >.........................DHFR.........................>

8041  ctcgccttgt tttctttttg tcaatcagaa cgaaagcgag ttgcgggtga cgcagatgtg
      >.........................DHFR.........................>

8101  cgtgtatcca ctcgtgaatg cgttatcgtt ctgtatgccg ctagagtgct ggactgttgc
      >.........................DHFR.........................>

8161  tgtctgccca cgacagcaga caactttcct tctatgcact tgcaggatgg tgcagcgcaa
      >.........................DHFR.........................>

8221  acgacggaga gaaaggagca ccctctcagt ttccctacga tgtgctgtca gtttcgactc
      >.........................DHFR.........................>

8281  ttcaccgcga acgattggcg atacgtctct gttgacttgt taggctccga ccacgaagct
      >.........................DHFR.........................>

8341  cccttaacta rataagccgc gacacctaag tgtacaccat ttgcagatcg ataatctgcg
      >.........................DHFR.........................>

8401  accgctgaat ccgtccagat cagtaaaacc gcaccaccta agtgtaaacc ttgtttaggt
      >.........................DHFR.........................>
```

```
8461  cgataaaatg ctaccaaccc ccacccacaa tcgagccttg agcgtttctg cgcacgcgtt
      >.....................DHFR.............................>

8521  ggcctacgtg acttgctgat gcctgcctct ggccattcat gccagtcagt gcgcataaaa
      >.....................DHFR.............................>

8581  atgtggacac agtcggttga caagtgttct ggcaggctac agtgacaccg cggtgagggg
      >.....................DHFR.............................>
                        NotI
                       ---------
8641  gatccactag tctagagcgg ccgccaccgc ggtggagctc caattcgccc tatagtgagt
      >.....DHFR.....>>
                                                    <<...T7....<

8701  cgtattacgc gcgctcactg gccgtcgttt tacaacgtcg tgactgggaa aaccctggcg
      <..T7...<<

8761  ttacccaact taatcgcctt gcagcacatc cccctttcgc cagctggcgt aatagcgaag

8821  aggcccgcac cgatcgccct tcccaacagt tgcgcagcct gaatggcgaa tgggacgcgc

8881  cctgtagcgg cgcattaagc gcggcgggtg tggtggttac gcgcagcgtg accgctacac

8941  ttgccagcgc cctagcgccc gctcctttcg ctttcttccc ttcctttctc gccacgttcg

9001  ccggctttcc ccgtcaagct ctaaatcggg ggctcccttt agggttccga tttagtgctt

9061  tacggcacct cgaccccaaa aaacttgatt agggtgatgg ttcacgtagt gggccatcgc

9121  cctgatagac ggtttttcgc cctttgacgt tggagtccac gttctttaat agtggactct

9181  tgttccaaac tggaacaaca ctcaacccta tctcggtcta ttcttttgat ttataaggga

9241  ttttgccgat ttcggcctat tggttaaaaa atgagctgat ttaacaaaaa tttaacgcga

9301  attttaacaa aatattaacg cttacaattt ag
```

TubYFP/TR-sagCAT

Molecule Features:

Type	Start	End	Name	Description
GENE	2172	2192	T3	T3 primer for sequencing
REGION	2271	2580	pSAG1	SAG1 5' region including promoter
REGION	2581	2583	SAG1 ATG-I	first ATG
GENE	2581	2634	SAG1 CDS	SAG1 coding sequence
REGION	2632	2634	SAG1 ATG-II	second ATG
GENE	2638	3294	CAT CDS	chloramphenicol acetyl transferase coding sequence
REGION	3295	3607	SAG1-I	SAG1 3' untranslated region
REGION	3614	3747	SAG1-II	repeated part of 3' untranslated region used to start tub promoter
REGION	3748	3799	vector	part of unknown vector
REGION	3800	6520	pTUB1	TUB1 5' region including promoter
GENE	6530	7246	YFP CDS	Yellow fluorescent protein coding sequence
REGION	6530	6532	YFP ATG-I	first ATG
GENE	7253	7876	TR CDS	Tet repressor coding sequence
REGION	7253	7255	TR ATG-I	first ATG
REGION	7886	8656	DHFR	DHFR 3' untranslated region
GENE	8710	8690 C	T7	T7 primer for sequencing

Map of tubYFP/TR-sagCAT:



Figure 2.

```
   1  agcttcctcg cagagattgt cagtgcatga cacaaccgcg aaaagccggc agccgcggta
      >>.....................'promoter.....................>

  61  atacggggac gaggaaaacg actgagcgtc acaacagaag cagccgagta aacggcgaag
      >.....................'promoter.....................>

 121  gaaatggaaa ggacccaagt aaaatttctt gaagaatttc agcgcaacaa ctctgcgggt
      >.....................'promoter.....................>

 181  tcttgcgaat agaggaattt cacttcctca tcgtctgatt tatgctttca tcatctgccg
      >.....................'promoter.....................>

 241  ctcaacagcc gaataaacgg ttctcggtcg cttccttaaa ctctacttca gtagttgaaa
      >.....................'promoter.....................>

 301  ctcttttgct tcacgagcct tcgtctcagc cctcaccgtc ctgagttctg tctttgttga
      >.....................'promoter.....................>

 361  ggaaagctcc cgctgaaaaa acaggacttt gtttgcagat tttcatgtgt actggaaagt
      >.....................'promoter.....................>

 421  gagatgtgac ttggggaagt ccgctttaaa atttccattg ttttctcaaa atgaaaagtc
      >.....................'promoter.....................>
                                              PstI
                                              -------
 481  taaaaaatcg aagtgcgtgc cccgcgagga attcccctct gcagatttgt tttgcattta
      >.....................'promoter.....................>

 541  tatgtcgttt ttacggagaa aagtcccaag ctgctgctcc ttctctaact agatgttgaa
      >.....................'promoter.....................>

 601  cgctagcaca tatgcaccag atgcttctga agtataccta aacgcacctt gggaacaact
      >.....................'promoter.....................>

 661  gtgctcccat tcataaaact catacaagtc accaagcatg ccataccgt gagacataac
      >.....................'promoter.....................>

 721  aacggaagct agactactcc cccctgttat tgcacactat cgaaaaggat tcctaggttt
      >.....................'promoter.....................>
                                PstI
                                -------
 781  ctatcctctg cctttttcctg gggcacactg cagagaaact accgtgcgcg ctacctcccg
      >.....................'promoter.....................>

 841  acgtgcgagg cgatagcaaa acgcttttga aggaaaaagt cgagaaatcg acgactgcgt
      >.....................'promoter.....................>

 901  ctcttgaatc cgagagaggg atccaaccca ccgagttctc tgcatgtgca gcatctgcaa
      >.....................'promoter.....................>
```

```
961  gaacgtgata atgcatgaac tcgatcatcg ccttatctgt gtgcatgcat tttcgaaaaa
     >.........................'promoter.........................>

1021 gaaaggcgtt ttctgcgcgg agactcgcgc ggaggcaaga cgagactttc tcctcttcca
     >.........................'promoter.........................>

1081 aactgcgagc cacgggggcg catgcaattt gaacatcacg caaaatccca aaacgggtgg
     >.........................'promoter.........................>

1141 ggtggagccg caaacttttt tggcatgcag cgttgagcct gagctgcggt gggggctttt
     >.........................'promoter.........................>

1201 gtcgcgagcg tggggtgccg cgagagagca acgcggcgct acgcggccga cgggtcttct
     >.........................'promoter.........................>

1261 gggaagcctc gcatttcctc gacgggttct cccctcaatt ctcttccttt ctctgcgtct
     >...........'promoter.....>>
                              >>.........e.........>

1321 tcctcaggtg gcttcgtcac cggtttttct cctcgcgttc gtgctccgct gtgtgtccgg
     >..'.............................e.............................>

1381 agtgccgcga cagatcgagg gcgttctccg ctcccacctt gcggttccca atttcgattt
     >.............................e.............................>

1441 ttctccgtca ccatggggcg catgtacggt cctggaaagg gcatgtctgc ctctaggatg
     >.........................e.........................>>
                 >>>
                 >>.................cds.................>>
                                                       >>...>

1501 accatgatta cggattcact ggccgtcgtt ttacaacgtc gtgactggga aaaccctggc
     >.........................'LacZ.........................>

1561 gttacccaac ttaatcgcct tgcagcacat cccccctttcg ccagctggcg taatagcgaa
     >.........................'LacZ.........................>

1621 gaggcccgca ccgatcgccc ttcccaacag ttgcgcagcc tgaatggcga atggcgcttt
     >.........................'LacZ.........................>

1681 gcctggtttc cggcaccaga agcggtgccg gaaagctggc tggagtgcga tcttcctgag
     >.........................'LacZ.........................>

1741 gccgatactg tcgtcgtccc ctcaaactgg cagatgcacg gttacgatgc gcccatctac
     >.........................'LacZ.........................>

1801 accaacgtga cctatcccat tacggtcaat ccgccgtttg ttcccacgga gaatccgacg
     >.........................'LacZ.........................>

1861 ggttgttact cgctcacatt taatgttgat gaaagctggc tacaggaagg ccagacgcga
     >.........................'LacZ.........................>

1921 attatttttg atggcgttaa ctcggcgttt catctgtggt gcaacgggcg ctgggtcggt
```

```
>.............................'LacZ.............................>

1981  tacggccagg acagtcgttt gccgtctgaa tttgacctga gcgcattttt acgcgccgga
      >.............................'LacZ.............................>

2041  gaaaaccgcc tcgcggtgat ggtgctgcgc tggagtgacg gcagttatct ggaagatcag
      >.............................'LacZ.............................>

2101  gatatgtggc ggatgagcgg cattttccgt gacgtctcgt tgctgcataa accgactaca
      >.............................'LacZ.............................>

2161  caaatcagcg atttccatgt tgccactcgc tttaatgatg atttcagccg cgctgtactg
      >.............................'LacZ.............................>

2221  gaggctgaag ttcagatgtg cggcgagttg cgtgactacc tacgggtaac agtttcttta
      >.............................'LacZ.............................>

2281  tggcagggtg aaacgcaggt cgccagcggc accgcgcctt tcggcggtga aattatcgat
      >.............................'LacZ.............................>

2341  gagcgtggtg gttatgccga tcgcgtcaca ctacgtctga acgtcgaaaa cccgaaactg
      >.............................'LacZ.............................>

2401  tggagcgccg aaatcccgaa tctctatcgt gcggtggttg aactgcacac cgccgacggc
      >.............................'LacZ.............................>

2461  acgctgattg aagcagaagc ctgcgatgtc ggtttccgcg aggtgcggat tgaaaatggt
      >.............................'LacZ.............................>

2521  ctgctgctgc tgaacggcaa gccgttgctg attcgaggcg ttaaccgtca cgagcatcat
      >.............................'LacZ.............................>

2581  cctctgcatg gtcaggtcat ggatgagcag acgatggtgc aggatatcct gctgatgaag
      >.............................'LacZ.............................>

2641  cagaacaact ttaacgccgt gcgctgttcg cattatccga accatccgct gtggtacacg
      >.............................'LacZ.............................>

2701  ctgtgcgacc gctacggcct gtatgtggtg gatgaagcca atattgaaac ccacggcatg
      >.............................'LacZ.............................>

2761  gtgccaatga atcgtctgac cgatgatccg cgctggctac cggcgatgag cgaacgcgta
      >.............................'LacZ.............................>

2821  acgcgaatgg tgcagcgcga tcgtaatcac ccgagtgtga tcatctggtc gctggggaat
      >.............................'LacZ.............................>

2881  gaatcaggcc acggcgctaa tcacgacgcg ctgtatcgct ggatcaaatc tgtcgatcct
      >.............................'LacZ.............................>

2941  tcccgcccgg tgcagtatga aggcggcgga gccgacacca cggccaccga tattatttgc
```

>.....'LacZ.....>

3001 ccgatgtacg cgcgcgtgga tgaagaccag ccgttcccgg ctgtgccgaa atggtccatc
>.....'LacZ.....>

3061 aaaaaatggc tttcgctacc tggagagacg cgcccgctga tcctttgcga atacgcccac
>.....'LacZ.....>

3121 gcgatgggta acagtcttgg cggtttcgct aaatactggc aggcgtttcg tcagtatccc
>.....'LacZ.....>

3181 cgtttacagg gcggcttcgt ctgggactgg gtggatcagt cgctgattaa atatgatgaa
>.....'LacZ.....>

3241 aacggcaacc cgtggtcggc ttacggcggt gattttggcg atacgccgaa cgatcgccag
>.....'LacZ.....>

3301 ttctgtatga acggtctggt ctttgccgac cgcacgccgc atccagcgct gacggaagca
>.....'LacZ.....>

3361 aaacaccagc agcagttttt ccagttccgt ttatccgggc aaaccatcga agtgaccagc
>.....'LacZ.....>

3421 gaatacctgt tccgtcatag cgataacgag ctcctgcact ggatggtggc gctggatggt
>.....'LacZ.....>

3481 aagccgctgg caagcggtga agtgcctctg gatgtcgctc cacaaggtaa acagttgatt
>.....'LacZ.....>

3541 gaactgcctg aactaccgca gccggagagc gccgggcaac tctggctcac agtacgcgta
>.....'LacZ.....>

3601 gtgcaaccga acgcgaccgc atggtcagaa gccgggcaca tcagcgcctg gcagcagtgg
>.....'LacZ.....>

3661 cgtctggcgg aaaacctcag tgtgacgctc cccgccgcgt cccacgccat cccgcatctg
>.....'LacZ.....>

3721 accaccagcg aaatggattt ttgcatcgag ctgggtaata agcgttggca atttaaccgc
>.....'LacZ.....>

3781 cagtcaggct ttctttcaca gatgtggatt ggcgataaaa aacaactgct gacgccgctg
>.....'LacZ.....>

3841 cgcgatcagt tcacccgtgc accgctggat aacgacattg gcgtaagtga agcgacccgc
>.....'LacZ.....>

3901 attgaccota acgcctgggt cgaacgctgg aaggcggcgg gccattacca ggccgaagca
>.....'LacZ.....>

3961 gcgttgttgc agtgcacggc agatacactt gctgatgcgg tgctgattac gaccgctcac

```
      >.............................'LacZ.............................>

4021  gcgtggcagc atcaggggaa aaccttattt atcagccgga aaacctaccg gattgatggt
      >.............................'LacZ.............................>

4081  agtggtcaaa tggcgattac cgttgatgtt gaagtggcga gcgatacacc gcatccggcg
      >.............................'LacZ.............................>

4141  cggattggcc tgaactgcca gctggcgcag gtagcagagc gggtaaactg gctcggatta
      >.............................'LacZ.............................>

4201  gggccgcaag aaaactatcc cgaccgcctt actgccgcct gttttgaccg ctgggatctg
      >.............................'LacZ.............................>

4261  ccattgtcag acatgtatac ccccgtacgtc ttcccgagcg aaaacggtct gcgctgcggg
      >.............................'LacZ.............................>

4321  acgcgcgaat tgaattatgg cccacaccag tggcgcggcg acttccagtt caacatcagc
      >.............................'LacZ.............................>

4381  cgctacagtc aacagcaact gatggaaacc agccatcgcc atctgctgca cgcggaagaa
      >.............................'LacZ.............................>

4441  ggcacatggc tgaatatcga cggtttccat atggggattg gtggcgacga ctcctggagc
      >.............................'LacZ.............................>

4501  ccgtcagtat cggcggaatt ccagctgagc gccggtcgct accattacca gttggtctgg
      >.............................'LacZ.............................>
                    PstI
                    ------
4561  tgtcaaaaat aactgcagcc cacagaagct gcccgtctct cgttttcctc tcttttcgga
      >.....'LacZ......>>
                           >>.................DHFR .................>

4621  gggatcaggg agagtgcctc gggtcggaga gagctgacga gggggtgcca gagacccctg
      >.............................DHFR .............................>

4681  tgtcctttat cgaagaaaag ggatgactct tcatgtggca tttcacacag tctcacctcg
      >.............................DHFR .............................>

4741  ccttgttttc tttttgtcaa tcagaacgaa agcgagttgc gggtgacgca gatgtgcgtg
      >.............................DHFR .............................>

4801  tatccactcg tgaatgcgtt atcgttctgt atgccgctag agtgctggac tgttgctgtc
      >.............................DHFR .............................>

4861  tgcccacgac agcagacaac tttccttcta tgcacttgca ggatggtgca gcgcaaacga
      >.............................DHFR .............................>

4921  cggagagaaa ggagcaccct ctcagtttcc ctacgatgtg ctgtcagttt cgactcttca
      >.............................DHFR .............................>
```

```
4981  ccgcgaacga ttggcgatac gtctctgttg acttgttagg ctccgaccac gaagctccct
      >..........................DHFR ............................>

5041  taactarata agccgcgaca cctaagtgta caccatttgc agatcgataa tctgcgaccg
      >..........................DHFR ............................>

5101  ctgaatccgt ccagatcagt aaaaccgcac cacctaagtg taaaccttgt ttaggtcgat
      >..........................DHFR ............................>

5161  aaaatgctac caaccccac ccacaatcga gccttgagcg tttctgcgca cgcgttggcc
      >..........................DHFR ............................>

5221  tacgtgactt gctgatgcct gcctctggcc attcatgcca gtcagtgcgc ataaaaatgt
      >..........................DHFR ............................>

5281  ggacacagtc ggttgacaag tgttctggca ggctacagtg acaccgcggt ggaggggat
      >..........................DHFR ............................>
                          NotI
                        ---------
5341  ccactagttc tagagcggcc gccaccgcgg tggagctcca attcgcccta tagtgagtcg
      >...DHFR ....>>
                                                            <<....T7.....<

5401  tattacgcgc gctcactggc cgtcgtttta caacgtcgtg actgggaaaa ccctggcgtt
      <.T7..<<
             >>.......................pKS+..........................>

5461  acccaactta atcgccttgc agcacatccc cctttcgcca gctggcgtaa tagcgaagag
      >...........................pKS+............................>

5521  gcccgcaccg atcgcccttc ccaacagttg cgcagcctga atggcgaatg ggacgcgccc
      >...........................pKS+............................>

5581  tgtagcggcg cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt
      >...........................pKS+............................>

5641  gccagcgccc tagcgcccgc tcctttcgct ttcttccctt cctttctcgc cacgttcgcc
      >...........................pKS+............................>

5701  ggctttcccc gtcaagctct aaatcggggg ctccctttag ggttccgatt tagtgcttta
      >...........................pKS+............................>

5761  cggcacctcg accccaaaaa acttgattag ggtgatggtt cacgtagtgg gccatcgccc
      >...........................pKS+............................>

5821  tgatagacgg tttttcgccc tttgacgttg gagtccacgt tctttaatag tggactcttg
      >...........................pKS+............................>

5881  ttccaaactg gaacaacact caaccctatc tcggtctatt cttttgattt ataagggatt
      >...........................pKS+............................>

5941  ttgccgattt cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat
```

```
>.....pKS+.....>

6001  tttaacaaaa tattaacgct tacaatttag gtggcacttt tcggggaaat gtgcgcggaa
      >.....pKS+.....>

6061  cccctatttg tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac
      >.....pKS+.....>

6121  cctgataaat gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg
      >.....pKS+.....>

6181  tcgcccttat tccctttttt gcggcatttt gccttcctgt ttttgctcac ccagaaacgc
      >.....pKS+.....>

6241  tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg
      >.....pKS+.....>

6301  atctcaacag cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga
      >.....pKS+.....>

6361  gcacttttaa agttctgcta tgtggcgcgg tattatcccg tattgacgcc gggcaagagc
      >.....pKS+.....>

6421  aactcggtcg ccgcatacac tattctcaga atgacttggt tgagtactca ccagtcacag
      >.....pKS+.....>

6481  aaaagcatct tacggatggc atgacagtaa gagaattatg cagtgctgcc ataaccatga
      >.....pKS+.....>

6541  gtgataacac tgcggccaac ttacttctga caacgatcgg aggaccgaag gagctaaccg
      >.....pKS+.....>

6601  ctttttgca caacatgggg gatcatgtaa ctcgccttga tcgttgggaa ccggagctga
      >.....pKS+.....>

6661  atgaagccat accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt
      >.....pKS+.....>

6721  tgcgcaaact attaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact
      >.....pKS+.....>

6781  ggatggaggc ggataaagtt gcaggaccac ttctgcgctc ggcccttccg gctggctggt
      >.....pKS+.....>

6841  ttattgctga taaatctgga gccggtgagc gtgggtctcg cggtatcatt gcagcactgg
      >.....pKS+.....>

6901  ggccagatgg taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta
      >.....pKS+.....>
```

```
6961  tggatgaacg aaatagacag atcgctgaga taggtgcctc actgattaag cattggtaac
      >...........................pKS+..............................>

7021  tgtcagacca agtttactca tatatacttt agattgattt aaaacttcat ttttaattta
      >...........................pKS+..............................>

7081  aaaggatcta ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt
      >...........................pKS+..............................>

7141  tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt
      >...........................pKS+..............................>

7201  tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt
      >...........................pKS+..............................>

7261  gtttgccgga tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc
      >...........................pKS+..............................>

7321  agataccaaa tactgtcctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg
      >...........................pKS+..............................>

7381  tagcaccgcc tacatacctc gctctgctaa tcctgttacc agtggctgct gccagtggcg
      >...........................pKS+..............................>

7441  ataagtcgtg tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggt
      >...........................pKS+..............................>

7501  cgggctgaac ggggggttcg tgcacacagc ccagcttgga gcgaacgacc tacaccgaac
      >...........................pKS+..............................>

7561  tgagatacct acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg
      >...........................pKS+..............................>

7621  acaggtatcc ggtaagcggc agggtcggaa caggagagcg cacgagggag cttccagggg
      >...........................pKS+..............................>

7681  gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat
      >...........................pKS+..............................>

7741  ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt
      >...........................pKS+..............................>

7801  tacggttcct ggccttttgc tggccttttg ctcacatgtt ctttcctgcg ttatcccctg
      >...........................pKS+..............................>

7861  attctgtgga taaccgtatt accgcctttg agtgagctga taccgctcgc cgcagccgaa
      >...........................pKS+..............................>

7921  cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga gcgcccaata cgcaaaccgc
      >...........................pKS+..............................>
```

```
7981  ctctccccgc gcgttggccg attcattaat gcagctggca cgacaggttt cccgactgga
      >.............................pKS+.............................>

8041  aagcgggcag tgagcgcaac gcaattaatg tgagttagct cactcattag gcaccccagg
      >.............................pKS+.............................>

8101  ctttacactt tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga taacaatttc
      >.............................pKS+.............................>

8161  acacaggaaa cagctatgac catgattacg ccaagcgcgc aattaaccct cactaaaggg
      >.....................pKS+.....................>>
                                                     >>.......T3 .......>
                  KpnI                                    HindIII
                  ------                                  ------
8221  aacaaaagct gggtaccggg cccccccctcg aggtcgacgg tatcgata
      >>
```



Molecule: S13/lacZ, 8268 bps DNA Circular

Molecule Features:

Type	Start	End		Name	Description
REGION	1	1294		'promoter	promoterregio
REGION	1295	1492		e	exon 1
REGION	1453	1455		atg	ATG start
GENE	1453	1492		cds	gen
GENE	1495	4578		'LacZ	LacZ gene from E.coli BL21
REGION	4582	5354		DHFR	DHFR 3' untranslated region
GENE	5408	5388	C	T7	T7 primer for sequencing
REGION	5408	8202		pKS+	pKS+ vector
GENE	8202	8222		T3	T3 primer for sequencing

Figure 3.

-324 caaaacgggt ggggtggagc cgcaaacttt tttggcatgc agcgttgagc ctgagctgcg gtgggggctt ttgtcgcgag cgtggggtgc

Substitutie -23

tccct atcagtgata gagatc

STS

-234 cgcgagagag caacgcggcg ctacgcggcc gacgg*gtctt ctgggaagcc tcgcat*ttcc tcgacgggtt ctccccctcaa ttctcttcct

ccctatcagtgatagagatc

Insertie +3

-144 ttctctgcgt cttcctcagg tggcttcgtc accggttttt ctcctcgcgt tcgtgctccg ctgtgtgtcc ggagtgccgc gacagatcga

-54 gggcgttctc cgctcccacc ttgcggttcc caatttcgat ttttctccgt caccatgggg cgc

m g r


TubYFP/TR (50% of total lysate)
after 1 day of incubation
OD570 nm
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
S13/LZ(1.25(10)6)
S13i+3(1.25(10)6)
S13s-23(1.25(10)6)
-
Atc 1ug/ml
Tc 1ug/ml

Figure 4.



Figure 5.